CGEN Key Stats
|Revenue (Quarterly YoY Growth)||1372%|
|EPS Diluted (TTM)||-0.4383|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-16.53M|
|Gross Profit Margin (Quarterly)||7.86%|
|Profit Margin (Quarterly)||-298.2%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- Drug developer Compugen sees boost from Bayer oncology deal Nov 25
- Compugen Is Doing Something Amazing Nov 22
- PDL BioPharma Earnings Projected to Increase Nov 4
- Compugen Ltd. Reports Third Quarter 2013 Financial Results noodls Oct 30
- Compugen's CEO Discusses Q3 2013 Results - Earnings Call Transcript Seeking Alpha Oct 29
- Compugen Ltd (CGEN) Reports Q3 Loss of $0.12/Share Street Insider Oct 29
- Compugen Ltd. Reports Third Quarter 2013 Financial Results Business Wire Oct 29
- Compugen's Zarek Named Executive of the Year on CRN's Solution Provider 500 List Marketwired Oct 25
- Compugen Third Quarter 2013 Conference Call Scheduled for Tuesday, October 29, 2013 at 10:00 AM EST Business Wire Oct 22
- The Evolution Of Compugen: Is The Titan Arum Finally Ready To Bloom? Oct 17
CGEN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Compugen is up 106.0% over the last year vs S&P 500 Total Return up 30.90%, Seattle Genetics up 73.59%, and Coronado Biosciences down 61.66%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for CGEN
Pro Report PDF for CGEN
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CGEN Pro Report PDF
Pro Strategies Featuring CGEN
Did Compugen make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Compugen, Ltd., is a therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology.